Abu Dhabi fast-tracks access to new IBD medication

It is the first outside the US to offer the treatment.

The Department of Health – Abu Dhabi (DoH), in partnership with Johnson & Johnson and Sheikh Shakhbout Medical City (SSMC), have expedited access to Tremfya®, a biologic medication for Inflammatory Bowel Disease (IBD).

SSMC’s specialised IBD centre will administer the treatment to patients under the DoH’s supervision.

“By being the first outside the US to offer Tremfya® for both Crohn's disease and ulcerative colitis, we are reinforcing our dedication to strategic partnerships and innovative treatments that address chronic diseases,” said Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH.

The treatment is approved for adults with moderately to severely active ulcerative colitis and Crohn’s disease.

It is designed to help patients reach clinical remission and reduce disease symptoms.